aTyr Pharma, Inc.
ATYR
|
NASDAQ
|
1 Sledující
Company Quality
Profitability Score
9/100
Solvency Score
57/100
Dividends
Dividends data currently unavailable.Earnings
8/11/2025
in 31 days
-
Revenue est.
-
EPS est.
My Notes
You haven't added any notes for this stock yet. Use this space to record your insights or strategies.
Profile
Healthcare
Sektor
Biotechnology
Průmysl
Sanjay S. Shukla
CEO
56
Zaměstnanci
San Diego
Centrála
US
Země
Key Metrics TTM
Valuation
Market cap.
$462MEnterprise Value
$465MPrice to Earnings
-7.08Price to Sales
0.00Price to Book
5.98Price to Cash Flow
-7.43Profitability
Return on Assets
-65.21%Return on Equity
-86.87%Return on Invested Capital
-76.32%Gross Margin
0.00%Operating Margin
0.00%Net Margin
0.00%Liquidity
Quick Ratio
7.79Current Ratio
7.79Cash Ratio
0.97Inventory Turnover
0.00Asset Turnover
0.00Total Liabilities
$22MSolvency
Debt to Assets
0.13Debt to Equity
N/AInterest Coverage
0.00Equity Ratio
0.77Long-term Debt to Cap.
0.00Altman Z-Score
0.77Equity Peers
Equity peers currently unavailable.
Performance
Earnings Waterfall
Debt level and coverage
Earnings
Feed
There are no posts to show right now.